We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
In the latest close session, CRISPR Therapeutics AG (CRSP - Free Report) was down 3.05% at $66.06. The stock's performance was behind the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the Nasdaq, a tech-heavy index, added 0.18%.
Heading into today, shares of the company had gained 42.97% over the past month, outpacing the Medical sector's gain of 2.39% and the S&P 500's gain of 5.71%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. The company's upcoming EPS is projected at -$1.47, signifying a 1.34% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $6.58 million, up 1165.77% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$5.61 per share and a revenue of $41.42 million, demonstrating changes of -29.26% and +11%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 1.38% fall in the Zacks Consensus EPS estimate. At present, CRISPR Therapeutics AG boasts a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest close session, CRISPR Therapeutics AG (CRSP - Free Report) was down 3.05% at $66.06. The stock's performance was behind the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the Nasdaq, a tech-heavy index, added 0.18%.
Heading into today, shares of the company had gained 42.97% over the past month, outpacing the Medical sector's gain of 2.39% and the S&P 500's gain of 5.71%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. The company's upcoming EPS is projected at -$1.47, signifying a 1.34% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $6.58 million, up 1165.77% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$5.61 per share and a revenue of $41.42 million, demonstrating changes of -29.26% and +11%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 1.38% fall in the Zacks Consensus EPS estimate. At present, CRISPR Therapeutics AG boasts a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.